树突状细胞外泌体作为疫苗载体的研究进展

中图分类号：R730.3 文献标志码：A DOI：10.11958/20252450

esearchprogressofdendriticcellexosomesasvaccinecarriers

XU Tong1， ZHANG Wei²，LIU Yonghui2△ 1FirstTeachingHospitalofTanjinUniversityofTraditionalChineseMedicine，NationalClinicalResearch CenterforChnese Medicine Acupuncture and Moxibustion， Tianjin 30oo73， China;2School of Chemistry，Tiangong University Corresponding Author E -mail： liuyonghui@tiangong.edu.cn

Abstract：Tumorvaccinesfacechallengessuchaslowantigendeliveryeficiencyandsignificantsideeffectsofcarriers in stimulatingspecificnti-tumorimmunity.Dendriticcell-derived exosomes （Dex），asendogenous nanovesicles，providea newstrategyforthedevelopmentofnovelvaccinecarrersduetoteirexcellentbiocompatibility，targeteddeliverycapability andtheabilitytoload intrinsicimmune-active molecules.Dexcaneficientlydeliver tumorantigens，directlyactivate T，B and NKcells or indirectlypromote antigencross-presentation，andreshape the immune-suppresive microenvironment， therebytrigering a potent anti-tumor immune response.Studies have shown that Dex-based vaccines exhibit significant efcts in inhibiting tumor growth and prolonging survival in models such ashepatocellular carcinoma and melanoma.This reviewsummarizes thebiological propertiesof Dex，itsadvantages asavaccinecarrierandtheesearch progressindifrent tumorimmunotherapies，aiming to providereferencesand ideas forfurtherresearchonDexinthe fieldofvaccinecarriers and to promotebreakthroughs in its clinical application. Key words： dendriticcells; exosomes; immunotherapy;tumor vaccine;anti-tumor immunity; vaccine carier

肿瘤的免疫治疗，尤其是治疗性疫苗的开发，在诱导强效且特异的抗肿瘤免疫应答方面仍面临诸多挑战，如抗原递送效率不足、免疫原性有限等[1]。（剩余16031字）